Patents by Inventor Michael Van Zandt

Michael Van Zandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA
    Publication number: 20240018169
    Abstract: The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.
    Type: Application
    Filed: August 28, 2023
    Publication date: January 18, 2024
    Inventors: Anna Marie Pyle, Olga Fedorova, Erik Jagdmann, Michael Van Zandt, Lin Yuan, Albert DeBerardinis
  • N-Linked Glycosylation Inhibitors and Methods of Using Same
    Publication number: 20240010641
    Abstract: The present disclosure includes compounds, compositions, and methods for preventing, ameliorating, and/or treating diseases associated with N-linked glycosylation and/or oligosaccharyltransferase function in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound and/or pharmaceutical composition of the disclosure.
    Type: Application
    Filed: August 31, 2021
    Publication date: January 11, 2024
    Inventors: Joseph N. Contessa, Michael Van Zandt
  • Compositions and methods for inhibiting group II intron RNA
    Patent number: 11739104
    Abstract: The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 29, 2023
    Assignee: YALE UNIVERSITY
    Inventors: Anna Pyle, Olga Fedorova, Erik Gunnar Jagdmann, Michael Van Zandt, Lin Yuan, Albert DeBerardinis
  • Arginase inhibitors as therapeutics
    Patent number: 11389464
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 19, 2022
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
    Patent number: 11370754
    Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: June 28, 2022
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Michael Van Zandt, Jennifer L. Savoy
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210261573
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 26, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
  • Compositions and methods for inhibiting arginase activity
    Patent number: 11021495
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • METHOD OF PREPARING (3R,4S)-3-ACETAMIDO-4-ALLYL-N-(TERT-BUTYL)PYRROLIDINE-3-CARBOXAMIDE
    Publication number: 20210155589
    Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 27, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Michael VAN ZANDT, Jennifer L. SAVOY
  • COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA
    Publication number: 20210139512
    Abstract: The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 13, 2021
    Inventors: Anna Pyle, Olga Fedorova, Erik Gunnar Jagdmann, Michael Van Zandt, Lin Yuan, Albert DeBerardinis
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210061822
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10851118
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 1, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10844080
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: November 24, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20200339607
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: February 14, 2020
    Publication date: October 29, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Lene Raunkjær PETERSEN
  • Arginase Inhibitors as Therapeutics
    Publication number: 20200246362
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 6, 2020
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20200223872
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
  • Arginase inhibitors as therapeutics
    Patent number: 10603330
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 31, 2020
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10597411
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 24, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • Inhibitors of arginase and their therapeutic applications
    Patent number: 10538537
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: January 21, 2020
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Adam Golebiowski, Min K. Ji, Darren Whitehouse, Todd Ryder, Raymond P. Beckett
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20190330244
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 31, 2019
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjær PETERSEN
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10287303
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 14, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen